TLSI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
11.4M
+28.2%
8.9M
-32.6%
13.2M
+14.2%
11.6M
+3.1%
11.2M
Cost of Revenue
1.5M
+22.6%
1.2M
-30.2%
1.8M
-7.6%
1.9M
+5.8%
1.8M
Gross Profit
9.9M
+29.1%
7.7M
-33.0%
11.4M
+18.5%
9.7M
+2.6%
9.4M
Operating Expenses
20.7M
+28.8%
16.1M
+9.3%
14.7M
-21.2%
18.7M
+16.4%
16.0M
R&D
3.1M
-2.5%
3.2M
+25.1%
2.6M
-50.3%
5.2M
+41.0%
3.7M
SG&A
16.6M
+28.8%
12.9M
+5.9%
12.1M
-10.0%
13.5M
+3.3%
13.1M
Operating Income
-10809000
-28.5%
-8411000
-157.1%
-3271000
+63.7%
-9014000
-35.9%
-6632000
EBITDA
-10673000
-29.0%
-8276000
-163.1%
-3145000
+64.5%
-8851000
-36.9%
-6467000
Net Income
-9187000
-696.9%
1.5M
+115.8%
-9753000
+9.8%
-10811000
-30.4%
-8288000
EPS (Basic)
$-0.16
-633.3%
$0.03
+114.3%
$-0.21
+78.1%
$-0.96
-255.6%
$-0.27
EPS (Diluted)
$-0.16
-633.3%
$0.03
+114.3%
$-0.21
+78.1%
$-0.96
-255.6%
$-0.27
Shares (Diluted)
58.3M
+11.4%
52.3M
+11.1%
47.1M
+9.4%
43.1M
+30.9%
32.9M
TriSalus Life Sciences (TLSI) โ€” Financials